🧾 What This Document Is

This is a Form 6-K from GSK, a monthly update required for foreign companies listed on U.S. stock exchanges. It's a news release announcing a major regulatory milestone for one of its key drugs.

👉 In simple terms: GSK is telling the world, "Our promising new hepatitis B drug just cleared a major hurdle in the world's largest market for the disease."

🏢 What The Company Does & The Disease It's Targeting

GSK is a global pharmaceutical giant. This news is about its investigational drug, bepirovirsen, aimed at chronic hepatitis B (CHB).

• The Problem: Hepatitis B is a virus that can lead to chronic liver disease, liver cancer, and death. In China alone, an estimated 75 million people live with it, causing roughly 450,000 deaths per year.
• Current Limitations: Standard treatment often requires lifelong pills and rarely leads to a "functional cure," which occurs when the virus is undetectable after stopping treatment. Current cure rates are very low, around 1%.

🚀 The Big News: Regulatory Acceptance

GSK announced that China's regulatory agency, the National Medical Products Administration (NMPA), has officially accepted for review its application to market bepirovirsen.

👉 Why this matters: This is the "filed paperwork" step that starts the clock on a formal review process. Acceptance is a key milestone on the path to potential approval and sale.

• The drug was previously granted Breakthrough Therapy designation in China (August 2021), which is a status meant to speed up the development and review of drugs that show substantial promise.

📊 The Evidence: Clinical Trial Results

The submission is backed by data from two large Phase III trials (B-Well 1 & B-Well 2). Here’s what they found:

• The Result: Patients taking bepirovirsen on top of standard therapy had statistically significant and clinically meaningful higher rates of functional cure compared to those on standard therapy alone.
• Stronger in Some Patients: The effect was even greater in patients who started with lower levels of the virus's surface antigen (HBsAg).
• Safety: The drug's safety profile was acceptable and consistent with earlier studies.
• Full data will be presented at a medical congress in 2026.

🧪 How The Drug Works (The Science)

Bepirovirsen is a first-in-class drug called an antisense oligonucleotide (ASO). Think of it as a "search and destroy" agent.

👉 Analogy: If the virus is a factory making harmful proteins, bepirovirsen acts like a precision GPS-guided missile that finds the factory's blueprints (viral mRNA) and orders their destruction, shutting down production and helping the immune system regain control.

It works in three ways:

1. Stops the virus from copying itself.
2. Lowers levels of a key viral protein (HBsAg).
3. Helps stimulate the patient's own immune system.

⚖️ The Bigger Picture: Market & Competition

This filing is significant for several reasons:

• Massive Unmet Need: With 75 million patients in China and a high death toll, a successful functional cure represents a monumental market and public health opportunity.
• First-Mover Potential: The "first-in-class" and "Breakthrough Therapy" labels suggest GSK could be at the forefront of a new treatment paradigm if approved.
• Future Potential: GSK is already studying bepirovirsen as a potential "backbone" therapy for future combination treatments.

🔮 What's Next & The Risks

• The Path Ahead: The drug now enters the NMPA's review phase. The timeline for a decision isn't specified here, but breakthrough designations can accelerate this.
• It's Not Approved Yet: Bepirovirsen is not approved anywhere in the world. This is a major step, but the final approval is not guaranteed.
• Key Risk (⚠️): Regulatory review can be lengthy and unpredictable. There is always a risk that the agency could request more data, delay the decision, or, in a worst-case scenario, not grant approval based on the submitted evidence.

🧠 The Analogy

Developing a cure for chronic hepatitis B is like trying to reboot a computer that has a deep-seated virus. Current treatments just suppress the virus temporarily. Bepirovirsen aims to be the "master reset"—deleting the malicious code so the body's own operating system (the immune system) can start working properly again, all without needing constant antivirus software (lifelong pills).

📇 Key Contacts & People

Media Enquiries:

• Tim Foley: +44 (0) 20 8047 5502 (London)
• Sarah Clements: +44 (0) 20 8047 5502 (London)
• Kathleen Quinn: +1 202 603 5003 (Washington DC)
• Alison Hunt: +1 540 742 3391 (Washington DC)

Investor Relations:

• Constantin Fest: +44 (0) 7831 826525 (London)
• James Dodwell: +44 (0) 20 8047 2406 (London)
• Mick Readey: +44 (0) 7990 339653 (London)
• Steph Mountifield: +44 (0) 7796 707505 (London)
• Sam Piper: +44 (0) 7824 52779 (London)
• Jeff McLaughlin: +1 215 751 7002 (Philadelphia)
• Frannie DeFranco: +1 215 751 3126 (Philadelphia)

🧩 Final Takeaway

GSK's bepirovirsen, a potential first-in-class cure for hepatitis B, has cleared a major regulatory gate in China—a critical market with 75 million patients. The path to approval is now formally underway, backed by strong Phase III trial data, representing a significant near-term catalyst for the company's pipeline.